13th March 2017

TARGAXAN® (rifaximin-α)

THE ONLY LICENSED TREATMENT FOR THE REDUCTION IN RECURRENCE OF OVERT HEPATIC ENCEPHALOPATHY (OHE) 1

When should TARGAXAN® be prescribed?

TARGAXAN®
When to initiate TARGAXAN® How long should TARGAXAN® be prescribed?
After the first OHE episode to reduce the risk of further episodes. 1 Expert clinical opinion suggests that people may continue to use TARGAXAN® until death or until liver transplant. 2

How should you prescribe TARGAXAN®? 1

  • Licensed dose: 550 mg (one tablet) twice a day.
  • Each tablet contains 550 mg rifaximin-α.
  • TARGAXAN® can be administered with or without food.
  • No dosage adjustment needed in elderly patients and patients with renal or hepatic insufficiency.
  • Use with caution in patients with severe hepatic impairment and in patients with MELD (Model for End-Stage Liver Disease) score >25.
  • Use with caution in patients with impaired renal function.
TARGAXAN tablets

TARGAXAN® Tolerability 1

Common adverse reactions are dizziness, headache, depression, dyspnoea, upper abdominal pain, abdominal distension, diarrhoea, nausea, vomiting, ascites, rashes, pruritus, muscle spasms, arthralgia and peripheral oedema. 1

Click here for a more detailed look at TARGAXAN® tolerability


UKE-HEP-XIF-2000014   DOP: June 2020

References

  1. TARGAXAN® Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27427
  2. NICE. Costing report: Implementing the NICE guidance on rifaximin for preventing episodes of overt hepatic encephalopathy (TA337). Available at: https:// www.nice.org.uk/guidance/ta337/resources/costing-report-428453677

References

  1. TARGAXAN® Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27427
  2. NICE. Costing report: Implementing the NICE guidance on rifaximin for preventing episodes of overt hepatic encephalopathy (TA337). Available at: https:// www.nice.org.uk/guidance/ta337/resources/costing-report-428453677

References

  1. TARGAXAN® Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine/27427
  2. NICE. Costing report: Implementing the NICE guidance on rifaximin for preventing episodes of overt hepatic encephalopathy (TA337). Available at: https:// www.nice.org.uk/guidance/ta337/resources/costing-report-428453677